-
Treatment Decisions for Stable Chronic Obstructive Pulmonary Disease in China: An Observational Cross-Sectional Survey Based on Multivariate Discrete Choice Modeling
29 Oct 2025 00:29 GMT
Introduction
Chronic obstructive pulmonary disease (COPD), characterized by persistent airflow limitation … , Carone M. A perspective for chronic obstructive pulmonary disease (COPD) management: six key clinical questions …
-
GSK’s Respiratory Pipeline Adds an Early-Stage Drug Offering a Novel Approach to COPD
29 Oct 2025 00:41 GMT
… newly approved product for chronic obstructive pulmonary disease as well as … specifically covers patients whose COPD is characterized by … estimated 40% of COPD patients have disease driven by type … with assets across its COPD portfolio and pipeline. …
-
GSK adds to COPD drug push with Empirico deal
28 Oct 2025 22:03 GMT
… range of patients with chronic obstructive pulmonary disease, or COPD.
Empirico is currently testing … Nucala medicine to include COPD patients in 2018. After … people will suffer from the disease by 2050, with the … as smoking, co-morbid disease or the “type 2 …
-
Focusing on education, action for this year’s COPD Awareness Month
28 Oct 2025 17:57 GMT
… support those with chronic obstructive pulmonary disease (COPD). World COPD Day will be observed … the word about COPD and chronic lung disease awareness, prevention, … COPD Day, organized each year by the Global Initiative for Chronic Obstructive Lung Disease …
-
GSK strikes again, adding COPD candidate in $745m deal
28 Oct 2025 14:05 GMT
… to a drug for chronic obstructive pulmonary disease (COPD) from US biotech Empirico … a broad spectrum of COPD, including patients with non … patients with inadequately controlled COPD and high levels of … for COPD, but also only in patients whose disease is …
-
GSK licences siRNA COPD drug in US$745m biobucks deal
28 Oct 2025 14:54 GMT
… -based and biologic therapies for COPD:
Silence Therapeutics: siRNA candidates … targeting inflammatory pathways in COPD, preclinical to early clinical stage … molecule and biologic programmes for COPD exacerbations, including PDE4 inhibitors and …
-
GSK to license Empirico’s COPD candidate for $85M upfront
28 Oct 2025 13:18 GMT
-
Chronic Obstructive Pulmonary Disease Drugs Market to Reach USD 30.13 Billion by 2032
24 Oct 2025 06:48 GMT
… FDA Approvals Revolutionize Patient Care
Chronic obstructive pulmonary disease (COPD) drugs market is rapidly expanding … -Cost Therapies to Unlock Growth
Chronic obstructive pulmonary disease (COPD) drugs market faces significant challenges …
-
How Common is Polypharmacy in COPD Patients?
28 Oct 2025 00:01 GMT
… definitions of polypharmacy used within chronic obstructive pulmonary disease (COPD) populations; to list … attributed to polypharmacy in COPD patients.
Investigators conducted a … exclusively involved COPD patients, whereas 17 had mixed pulmonary populations. …
-
Chronic Disease Management Market to Reach US$ 17.1 Billion by 2033 | Astute Analytica
27 Oct 2025 23:54 GMT
… Fuel Next-Generation Chronic Disease Management Market Solutions
… -customization/chronic-disease-management-market
Chronic Disease Management Market Major … By Disease Type
Cardiovascular Diseases
Diabetes
Cancer
Asthma
Chronic Obstructive Pulmonary …